PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients

Clinical Cancer Research

Volumn 21, Issue 11, 2015, Pages 2530-2537

  De La Rochefordiere, Anne ^a   Kamal, Maud ^a   Floquet, Anne ^b   Thomas, Laurence ^b   Petrow, Peter ^a   Petit, Thierry ^c   Pop, Marius ^c   Fabbro, Michel ^d   Kerr, Christine ^d   Joly, Florence ^e   Sevin, Emmanuel ^e   Maillard, Sophie ^f   Cure, Herve ^f   Weber, Beatrice ^g   Brunaud, Claire ^g   Minsat, Mathieu ^h   Gonzague, Laurence ^h   Berton Rigaud, Dominique ⁱ   Aumont, Maud ⁱ   Gladieff, Laurence ^j   Peignaux, Karine ^k   Bernard, Virginie ^a   Leroy, Quentin ^a   Bieche, Ivan ^a   Margogne, Audrey ^a   Nadan, Anatereza ^a   Fourchotte, Virginie ^a   Diallo, Alhassane ^a   Asselain, Benard ^a   Plancher, Corine ^a   Armanet, Sebastien ^a   Beuzeboc, Philippe ^a   Scholl, Suzy M ^a   more..

^a INSTITUT CURIE   (France)

^b INSTITUT BERGONIÉ   (France)

^c CENTRE PAUL STRAUSS   (France)

^d CENTRE VAL D AURELLE   (France)

^e François Baclesse Center   (France)

^f INSTITUT JEAN GODINOT   (France)

^g CENTRE ALEXIS VAUTRIN   (France)

^h INSTITUT PAOLI CALMETTES   (France)

ⁱ UMR INSERM U892 CNRS 6299   (France)

^j INSTITUT CLAUDIUS REGAUD   (France)

^k Georges Francois Leclerc Cancer Centre   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN KINASE LKB1; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; RAS PROTEIN; STK11 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE MUTATION; HUMAN; LEUKOPENIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; ONCOGENE K RAS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PELVIS TUMOR; PHASE 2 CLINICAL TRIAL; PIK3CA GENE; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; STK11 GENE; SURVIVAL TIME; TREATMENT DURATION; TUMOR GENE; UTERINE CERVIX CANCER; VOMITING; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

ADULT; AGED; CETUXIMAB; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS;

EID: 84941245510     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2368     Document Type: Article

References (34)

1. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-53.
2. Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 2005;99:415-21.
3. Fuchs I, Vorsteher N, Buhler H, Evers K, Sehouli J, Schaller G, et al. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res 2007; 27:959-63.
4. Li Q, Tang Y, Cheng X, Ji J, Zhang J, Zhou X. EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix. Int J Clin Exp Pathol 2014;7:733-41.
5. Noordhuis MG, Eijsink JJ, Ten Hoor KA, Roossink F, Hollema H, Arts HJ, et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res 2009;15:7389-97.
6. Huang SF, Cheng SD, Chien HT, Liao CT, Chen IH, Wang HM, et al. Relationship between epidermal growth factor receptor gene copy number and protein expression in oral cavity squamous cell carcinoma. Oral Oncol 2012;48:67-72.
7. Perez-Regadera J, Sanchez-Munoz A, De-la-Cruz J, Ballestin C, Lora D, Garcia-Martin R, et al. Impact of epidermal growth factor receptor expression on disease-free survival and rate of pelvic relapse in patients with advanced cancer of the cervix treated with chemoradiotherapy. Am J Clin Oncol 2011;34:395-400.
8. Gaffney DK, Haslam D, Tsodikov A, Hammond E, Seaman J, Holden J, et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:922-8.
9. Fujii S, Uryu H, Akashi K, Suzuki K, Yamazaki M, Tahara M, et al. Clinical significance of KRAS gene mutation and epidermal growth factor receptor expression in Japanese patients with squamous cell carcinoma of the larynx, oropharynx and hypopharynx. Int J Clin Oncol 2013;18:454-63.
10. Tan EH, Goh C, Lim WT, Soo KC, Khoo ML, Tan T, et al. Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. Ann Oncol 2012;23:1010-6
11. Tinhofer I, Klinghammer K, Weichert W, Knodler M, Stenzinger A, Gauler T, et al. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximabdocetaxel treatment. Clin Cancer Res 2011;17:5197-204.
12. Giaccone G, Wang Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat Rev 2011;37:456-64
13. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011;29:3316-21.
14. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz-Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Ojesina AI, Lichtenstein L, Freeman
15. Arias-Pulido H, Joste N, Chavez A, Muller CY, Dai D, Smith HO, et al. Absence of epidermal growth factor receptor mutations in cervical cancer. Int J Gynecol Cancer 2008;18:749-54.
16. Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, et al. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer 2013;119:3776-83.
17. Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, et al. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res 2013;73:6770-9.
18. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol 2010;21:vii252-61.
19. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11: 21-8.
20. Licitra L, Storkel S, Kerr KM, Van Cutsem E, Pirker R, Hirsch FR, et al. Predictive value of epidermal growth factor receptor expression for firstline chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer 2013;49:1161-8.
21. Ibrahim EM, Abouelkhair KM, Al-Masri OA, Chaudry NC, Kazkaz GA. Cetuximab-based therapy is effective in chemotherapy-naive patients with advanced and metastatic non-small-cell lung cancer: A meta-Analysis of randomized controlled trials. Lung 2011;189:193-8.
22. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33-42.
23. Moore KN, Sill MW, Miller DS, McCourt C, De Geest K, Rose PG, et al. A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecol Oncol 2012;127:456-61
24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, SargentD, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
25. Shimizu T, Saijo N. [Common toxicity criteria: version 2.0, an improved reference for grading the adverse reaction of cancer treatment]. Nihon Rinsho 2003;61:937-42.
26. Schefter T, Winter K, Kwon JS, Stuhr K, Balaraj K, Yaremko BP, et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys 2014;88:101-5.
27. Schefter TE, Winter K, Kwon JS, Stuhr K, Balaraj K, Yaremko BP, et al. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys 2012;83:1179-84.
28. Zhu X, Zhang F, Zhang W, He J, Zhao Y, Chen X. Prognostic role of epidermal growth factor receptor in head and neck cancer: A meta-Analysis. J Surg Oncol 2013;108:387-97.
29. Pujol JL, Pirker R, Lynch TJ, Butts CA, Rosell R, Shepherd FA, et al. Metaanalysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer 2014;83:211-8.
30. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522. J Clin Oncol 2014;32:2940-50.
31. Schwarz JK, Payton JE, Rashmi R, Xiang T, Jia Y, Huettner P, et al. Pathwayspecific analysis of gene expression data identifies the PI3K/Akt pathway as a novel therapeutic target in cervical cancer. Clin Cancer Res 2012;18: 1464-71.
32. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 2009;20: 84-90.
33. Di BartolomeoM, Pietrantonio F, Perrone F, Dotti KF, Lampis A, Bertan C, et al. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. Target Oncol 2014;9:155-62.
34. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 2014;508:118-22.